Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €686.32B | 85.6x | 1.26 | €764.20 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €661.85B | 83.6x | 1.26 | €761.90 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | €350.05B | 28.1x | 1.31 | €79.90 | -19.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | €350.05B | 28.1x | 1.31 | €82.47 | -18% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | €335.14B | 23.7x | -0.44 | €138.94 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | €333.10B | 23.7x | -0.44 | €139.24 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | €298.31B | 61.3x | -2.81 | €168.42 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €241.40B | 20.7x | 0.13 | €95 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | €240.20B | 20.7x | 0.13 | €95.10 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | €223.48B | 19.6x | -5.89 | €33 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €124.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €61 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €192.29B | 30.8x | 3.22 | €122.90 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Xetra | Healthcare | Pharmaceuticals | €143.34B | 35x | -0.57 | €25.22 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Frankfurt | Healthcare | Pharmaceuticals | €143.18B | 35.1x | -0.57 | €25.30 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Xetra | Healthcare | Pharmaceuticals | €137.75B | 33.9x | -0.78 | €255.90 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Frankfurt | Healthcare | Pharmaceuticals | €136.76B | 33.6x | -0.78 | €255.25 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi SA | Xetra | Healthcare | Pharmaceuticals | €114.74B | 25.5x | -0.49 | €91.46 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Frankfurt | Healthcare | Pharmaceuticals | €114.74B | 25.5x | -0.49 | €91.32 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Xetra | Healthcare | Pharmaceuticals | €111.01B | 917.4x | -9.28 | €89.02 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Frankfurt | Healthcare | Pharmaceuticals | €110.74B | 918.2x | -9.28 | €88.97 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers | Xetra | Healthcare | Pharmaceuticals | €110.55B | -15.8x | 0.08 | €54.18 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Frankfurt | Healthcare | Pharmaceuticals | €110.02B | -15.8x | 0.08 | €54.07 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Xetra | Healthcare | Pharmaceuticals | €65.18B | 21.5x | -0.37 | €16.10 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK | Frankfurt | Healthcare | Pharmaceuticals | €65.18B | 21.5x | -0.37 | €32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Frankfurt | Healthcare | Pharmaceuticals | €65.18B | 21.5x | -0.37 | €15.83 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €60.03B | 22.3x | -3.23 | €138.20 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.4% Upside | Upgrade to Pro+ | |
Merck KGaA | Frankfurt | Healthcare | Pharmaceuticals | €60.03B | 22.3x | -3.23 | €136.80 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.1% Upside | Upgrade to Pro+ | |
UCB | Frankfurt | Healthcare | Pharmaceuticals | €35.29B | 147.9x | -5.17 | €185 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | Xetra | Healthcare | Pharmaceuticals | €20.62B | 13.2x | 1.35 | €140.45 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |